Mahmut Yıldız

Dr. Mahmut Yıldız


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2019 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
Halilibrahim CiftciHalilibrahim Ciftci
Halilibrahim Ciftci
NBNilüfer Bayrak
Nilüfer Bayrak
HYHatice YILDIRIM
Hatice YILDIRIM
MYMahmut Yıldız
Mahmut Yıldız
Mohamed O. RadwanMohamed O. Radwan
Mohamed O. Radwan
ATAmac Fatih TuYuN
Amac Fatih TuYuN

2 January 2020 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
NBNilüfer Bayrak
Nilüfer Bayrak
HYHatice YILDIRIM
Hatice YILDIRIM
MYMahmut Yıldız
Mahmut Yıldız
Mohamed O. RadwanMohamed O. Radwan
Mohamed O. Radwan
MOMasami Otsuka
Masami Otsuka
ATAmac Fatih TuYuN
Amac Fatih TuYuN

15 August 2022 in ACS Omega
Verified
Journal Article
Open access
AGAyse Mine Yilmaz Goler
Ayse Mine Yilmaz Goler
AJAyse Tarbin Jannuzzi
Ayse Tarbin Jannuzzi
NBNilüfer Bayrak
Nilüfer Bayrak
MYMahmut Yıldız
Mahmut Yıldız
HYHatice Yıldırım
Hatice Yıldırım
ATAmac Fatih TuYuN
Amac Fatih TuYuN
We managed to obtain three different series of 2,3-dimethyl-1,4-benzoquinones, named nonhalogenated and halogenated (brominated and chlorinated) PQ analogues, via the molecular hybridization strategy. Sixteen of eighteen hybrid molecules were selected by the National Cancer Institute (NCI) of Bethesda for their in vitro antiproliferative potential against the full NCI 60 cell line panel. The hybrid molecules (BrPQ5, CIPQ1, and CIPQ3) showed good growth inhibition at 10 μM concentration, particularly against breast cancer cell lines. As per the results obtained from in vitro antiproliferative evaluation, cytotoxic activities of the hybrid molecules (BrPQ5, CIPQ1, and CIPQ3) were evaluated with an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in T47D and MCF7 breast cancer and human umbilical vein endothelial (HUVEC) cells. Molecules exhibited cytotoxic activity, and especially, CIPQ1 showed remarkable cytotoxic activity and good selectivity on T47D and MCF7 cells. Furthermore, CIPQ1 could inhibit cell proliferation, cause apoptotic cell death and disturb the cell cycle in T47D and MCF7 cells. Additionally, CIPQ1 caused oxidative stress induction in both cells, more so in T47D. In vitro study results indicated that the anticancer activity of CIPQ1 was more prominent in T47D cells than in MCF7 cells. The compound CIPQ1 showed a prominent binding with JNK3 in silico. Thus, the obtained hybrid molecules via the molecular hybridization strategy of two important pharmacophores could be useful in the discovery of novel antiproliferative agents, and CIPQ1 could be considered a promising drug candidate.

14 October 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Halilibrahim CiftciHalilibrahim Ciftci
Halilibrahim Ciftci
Belgin SeverBelgin Sever
Belgin Sever
NBNilüfer Bayrak
Nilüfer Bayrak
MYMahmut Yıldız
Mahmut Yıldız
HYHatice YILDIRIM
Hatice YILDIRIM
ATAmac Fatih TuYuN
Amac Fatih TuYuN
Colorectal cancer (CRC) and breast cancer are leading causes of death globally, due to significant challenges in detection and management. The late-stage diagnosis and treatment failures require the discovery of potential anticancer agents to achieve a satisfactory therapeutic effect. We have previously reported a series of plastoquinone analogues to understand their cytotoxic profile. Among these derivatives, three of them (AQ-11, AQ-12, and AQ-15) were selected by the National Cancer Institute (NCI) to evaluate their in vitro antiproliferative activity against a panel of 60 human tumor cell lines. AQ-12 exhibited significant antiproliferative activity against HCT-116 CRC and MCF-7 breast cancer cells at a single dose and further five doses. MTT assay was also performed for AQ-12 at different concentrations against these two cells, implying that AQ-12 exerted notable cytotoxicity toward HCT-116 (IC50 = 5.11 ± 2.14 μM) and MCF-7 (IC50 = 6.06 ± 3.09 μM) cells in comparison with cisplatin (IC50 = 23.68 ± 6.81 μM and 19.67 ± 5.94 μM, respectively). This compound also augmented apoptosis in HCT-116 (62.30%) and MCF-7 (64.60%) cells comparable to cisplatin (67.30% and 78.80%, respectively). Molecular docking studies showed that AQ-12 bound to DNA, forming hydrogen bonding through the quinone scaffold. In silico pharmacokinetic determinants indicated that AQ-12 demonstrated drug-likeness with a remarkable pharmacokinetic profile for future mechanistic anti-CRC and anti-breast cancer activity studies.

10 November 2021 in Separation Science and Technology
Verified
Journal Article
Closed access
MLMelisa Lalikoglu
Melisa Lalikoglu
YAYavuz Selim Aşçı
Yavuz Selim Aşçı
BTBurcu Sırma Tarım
Burcu Sırma Tarım
MYMahmut Yıldız
Mahmut Yıldız
RARefik Arat
Refik Arat
Hydrophobic deep eutectic solvents (HDES) are new-generation green solvents that have emerged in recent years. In this study, the efficiency of using HDES as a solvent in separating acrylic acid from its aqueous solution by reactive extraction method was investigated. As a solvent, HDES prepared with a mixture of TOPO and menthol has been used for the recovery of acrylic acid for the first time. Physical properties of HDES mixtures such as density, viscosity, and refractive index were determined. In reactive extraction experiments, TOPO, one of the two basic components in the solvent, was also employed as an extractant. With the help of response surface methodology based on Box-Behnken design, the effect of the parameters of amount of extractant (0.1–0.9 g), Menthol/TOPO molar ratio (2–4), and initial acid concentration (3–9%) on the distribution coefficient was investigated and the model equation was formed. The highest distribution coefficient (D = 7.8) was achieved with the molar ratio of Menthol/TOPO is 2. Upon examining all the results obtained, it was seen that more than 90% of acrylic acid could be extracted from the aqueous phase to the organic phase. GRAPHICAL ABSTRACT

22 December 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Halilibrahim CiftciHalilibrahim Ciftci
Halilibrahim Ciftci
Belgin SeverBelgin Sever
Belgin Sever
NKNusret Kaya
Nusret Kaya
NBNilüfer Bayrak
Nilüfer Bayrak
MYMahmut Yıldız
Mahmut Yıldız
ATAmac Fatih TuYuN
Amac Fatih TuYuN
Colorectal cancer (CRC), breast cancer, and chronic myeloid leukemia (CML) are life-threatening malignancies worldwide. Although potent therapeutic and screening strategies have been developed so far, these cancer types are still major public health problems. Therefore, the exploration of more potent and selective new agents is urgently required for the treatment of these cancers. Quinones represent one of the most important structures in anticancer drug discovery. We have previously identified a series of quinone-based compounds (ABQ-1-17) as anti-CML agents. In the current work, ABQ-3 was taken to the National Cancer Institute (NCI) for screening to determine its in vitro antiproliferative effects against a large panel of human tumor cell lines at five doses. ABQ-3 revealed significant growth inhibition against HCT-116 CRC and MCF-7 breast cancer cells with 2.00 µM and 2.35 µM GI50 values, respectively. The MTT test also showed that ABQ-3 possessed anticancer effects towards HCT-116 and MCF-7 cells with IC50 values of 5.22 ± 2.41 μM and 7.46 ± 2.76 μM, respectively. Further experiments indicated that ABQ-3 induced apoptosis in both cell lines, and molecular docking studies explicitly suggested that ABQ-3 exhibited DNA binding in a similar fashion to previously reported compounds. Based on in silico pharmacokinetic prediction, ABQ-3 might display drug-like features enabling this compound to become a lead molecule for future studies.